Introduction
Recombinant vectors derived from retroviruses are widely used for the stable introduction of genes into cells. 1 Although the retroviral integration event to some extent appears to be non-random, 2 retroviruses integrate into many different host sites 3 and it has been shown that the site of integration can influence the expression level of introduced genes. 4 This unpredictable expression presents one of the major obstacles for the gene therapeutic application of recombinant retroviruses. Moreover, in some cell types, such as in undifferentiated embryonal carcinoma (EC) cells or normal embryo cells, in blood cells derived from transduced hemopoietic stem cells and in transgenic mice, expression could not be obtained from the viral promoter at all. [5] [6] [7] However, during propagation of wild-type viruses on such primitive cells, mutants with an extended host-range sometimes evolve. In this way, a mutant of polyoma virus (PyF101) that revealed mutations within its enhancer was isolated on F9 EC cells. 5 When the fragment encompassing this mutant enhancer was used to replace the Moloney murine leukemia virus (MoMLV) enhancer in a recombinant retroviral construct, expression was obtained in EC cells and in the mouse hemopoietic system. 8, 9 The discovery of locus control region (LCR) sequences has raised the expectation that well controlled expression levels of retrovirally introduced sequences will become feasible. LCR sequences are defined as regulatory units that confer a cell type-specific, copy number-dependent and integration site-independent expression pattern on a linked gene in transgenic animals. 10 Several LCRs have been isolated of which the human ␤-globin LCR is the one most extensively studied. [11] [12] [13] [14] [15] [16] [17] Here, our aim is to ensure expression of retrovirally introduced genes in T cells. This is of particular interest for gene therapy approaches in the treatment of AIDS and various hemopoietic malignancies. To accomplish this we employed the LCR of the gene encoding CD2, [18] [19] [20] [21] a cell surface molecule expressed on most thymocytes and probably on all peripheral T cells. 22 This LCR also acts on heterologous promoters, 19 suggesting that the CD2-LCR could perhaps also function on a retroviral promoter, thereby helping to overcome the heterogeneity of retroviral expression. However, LCRs do not naturally occur in an RNA form as they do when they are introduced within a retroviral transcription unit. The generation of the first retroviruses that contained the ␤-globin LCR was associated with difficulties in obtaining stable virus constructs and acceptable recombinant vector titers. [23] [24] [25] Extensive testing of a variety of such vectors has led to the identification of stable high-titer retroviral vectors that efficiently express the human ␤-globin gene in erythroid cells, although clonal variation in expression levels still occurred. 26, 27 So far, such elaborate studies have not been reported for the CD2-LCR.
In this study we use as a basic vector the recombinant retrovirus construct LgAL(⌬Mo+PyF101). 9 It contains the human adenosine deaminase (ADA) cDNA driven by the retroviral promoter. Furthermore, the wild-type enhancer in the MoMLV long terminal repeat (LTR) has been replaced by the enhancer of the PyF101 mutant of polyoma virus. This vector exhibited expression levels of introduced genes that equalled the levels of their endogenous counterparts in adenosine deaminase deficient T cells from a patient suffering from severe combined immunodeficiency disease (ADA − SCID) and in T cells isolated from a rhesus monkey transplanted with transduced bone marrow cells 28, 29 However, when transduced bone marrow cells were transplanted into mice and 6 months later peripheral blood mononuclear cells were examined, among six mice that were positive for the provirus only two were found to express human ADA. Moreover, expression levels did not correlate with proviral copy numbers. 30 The latter study showed that the hADA gene was silent at several integration sites. Hence, there is room for improvement of the regulation of ADA expression by this vector. Here we present the construction of LgAL(⌬Mo+PyF101) vectors with CD2-LCR inserts and their expression patterns in transgenic mice, in human ADA − SCID T cells, and in hemopoietic tissues of mice transplanted with transduced bone marrow cells.
Results

Expression of LgAL(⌬Mo+PyF101) vector in human T lymphocytes
To study the ADA expression levels of our basic vector LgAL(⌬Mo+PyF101) 9 in T cells we transduced human ADA − SCID T cells by cocultivation with the amphotropic recombinant retrovirus vector producing cell line POAM-P1. 31 Without applying any selection, we isolated four different T cell clones containing the retroviral construct, each exhibiting a unique insertion pattern. To quantify the hADA enzyme activity in these clones we measured their IL-2-induced proliferation in the presence of the cytotoxic ADA-substrate xylofuranosyl-adenine (Xyl-A) and the specific ADA inhibitor deoxycoformycin (dCF). This selection pressure does not affect the proliferation of T cells isolated from healthy individuals, whereas ADA − SCID T cells hardly survive. 28 As can be seen in Table 1 , three of the four clones showed a proliferation ). However, the fourth clone that contained three hADA provirus copies had a very low ADA activity. Only one quarter of the normal proliferation was found, indicating that neither of the three integrated proviruses was able to express ADA at a comparable level to that found in T cells from healthy individuals. This was further confirmed by zymogram analysis (not shown). These results demonstrate that the LgAL(⌬Mo+PyF101) construct is capable of expressing at a wild-type level. However, the expression level varied at least 12-fold between individual provirus copies, suggesting strong provirus integration site dependency for expression in human T cells. In an attempt to overcome this dependency we decided to generate retroviruses with the human CD2-LCR.
Retroviral vectors in transgenic mice
Four different transgenic mouse strains were generated carrying recombinant retroviral vector constructs with hADA cDNA inserts driven by the 5′ LTR ( Figure 1 ). One of these vectors contains wild-type MoMLV LTRs, a second vector has the wild-type LTR enhancers replaced by polyoma F101 enhancers. The two remaining vectors additionally contain 2.1 kb CD2-LCR fragments inserted in the forward orientation either 3′ of the hADA gene between the LTRs or in U3 of both LTRs. In the latter construct, the CD2-LCR in the 5′ LTR is placed outside the retroviral transcription unit.
Three to 17 founder mice were obtained for each construct. The majority of mice carried provirus concatamers with adjacent proviruses sharing their LTRs. This structure can best be explained by homologous recombination between the 3′ and 5′ LTRs of adjacent constructs. However, nearly every mouse contained nonrearranged constructs as well, allowing further analysis of these animals. Of all founder mice and their offspring, spleen, thymus, bone marrow, liver, heart, muscle and brain were isolated and subjected to ADA zymogram analysis. In this analysis, mouse and human ADA isozymes are electrophoretically separated and stained for enzymatic activity. Although endogenous ADA activity could readily be detected in all samples, hADA activity was not found (not shown). Thus, neither the polyoma F101 enhancer nor the CD2-LCR overcame the expression block for the MoMLV promoter in the germline.
Generation of CD2-locus control region containing retroviruses Previous studies with retroviral vectors containing the ␤-globin LCR showed genomic instability of the vector. [23] [24] [25] 27 Anticipating similar problems with retroviral vectors containing the CD2-LCR, we set out to make several different constructs. As vector backbone we used LgAL(⌬Mo+PyF101). A 2.1 kb HindIII 21 or a 0.88 kb AflII 20 CD2-LCR fragment was inserted either in the normal 5′ Ͼ 3′ orientation of the CD2-LCR (forward) or in the 3′ Ͼ 5′ orientation (reverse). As insertion site we used either the ClaI site, 3′ of the hADA cDNA, or the NheI site, in U3 of the 3′ LTR (see Figure 1) . As a consequence of retroviral replication, in cells transduced with the latter construct the CD2-LCR carrying U3 region will also be present in the 5′ LTR, thereby placing the CD2-LCR outside the retroviral transcription unit. With all these constructs, recombinant amphotropic retrovirus vector producing cell lines were made by transducing GP+envAm12 cells with supernatant of transfected GP+E-86 cells. The producer clones were analyzed for their titer on NIH/3T3 cells and for the presence of intact provirus insertions ( Figure 2 ). Southern blot analysis of genomic DNA digested with several restriction enzymes using various hADA and CD2-LCR fragments as probes revealed differences in retrovirus stability between the different retroviral constructs. Three of the eight CD2-LCR containing constructs frequently recombined. Since all clones were isolated after selection for ADA overexpression, the deletions most probably only occurred outside the hADA coding region. None of seven clones transduced with the vector carrying the 2.1 kb CD2-LCR inserted in the forward orientation in its LTR N2F showed a correct provirus structure (see Figure 2a) . Five of these recombined proviruses showed small deletions of approximately 200 bp; in the other two clones almost 2 kb of the provirus was deleted. Analysis with LCR probes revealed that many deletions involved LCR sequences, without clear preference for deleted regions within the LCR (one of the clones carried deletions at the 5′ end of the LCR, two at the 3′ end, two lost both ends, whereas only two still carried both ends of the LCR insert). Reversing the orientation of the 2.1 kb CD2-LCR in the LTRs alleviated most of the instability: eight out of 10 clones carried a correct provirus. The two recombined proviruses in this case exhibited large deletions of approximately 2 kb. The insertion of the 0.88 kb CD2-LCR into the ClaI site in the reverse orientation (C8R) also frequently resulted in recombinations: five out of 12 clones carried rearranged proviruses. Three clones showed a deletion of more than the inserted LCR length, one clone showed a deletion of approximately 600 bp, and a fifth clone demonstrated an enlarged provirus length (see Figure 2a ) suggesting duplication of retroviral sequences or insertion of foreign DNA. In contrast, the other five CD2-LCR containing constructs always rendered stable proviruses without detectable rearrangements. Of all constructs, producer cell clones containing a single provirus insertion and showing a unique integration pattern were used to determine their recombinant retroviral titers on NIH/3T3 cells. All CD2-LCR containing retroviral constructs gave titers in the same range as did the vector lacking the CD2-LCR (Figure 2b ). There was one exception of a clone carrying a rearranged construct with a significantly increased titer. Characterization of the specific recombination in this high-titer mutant will be described elsewhere.
hADA expression in transduced fibroblasts As a control for T cell specificity of the CD2-LCR in a retroviral context, mouse fibroblasts, in which the CD2-LCR should be inactive, were transduced with recombinant vectors. Three different high-titer virus producers were used, containing the following intact provirus constructs: the LgAL(⌬Mo+PyF101) vector; C2F, the construct with the large CD2-LCR fragment in the ClaI site 3′ of the hADA gene; and N8F, with the small CD2-LCR fragment present in the LTRs. Transduced fibroblast pools and clones were analyzed for proviral copy numbers by Southern analysis and for ADA activity by zymogram analysis. The results from these analyses were used to calculate the human ADA activity per provirus insertion. Human ADA expression in cells transduced with LCR viruses appeared somewhat lower than in cells transduced with the control vector lacking the CD2-LCR (Table 2) . This difference was less profound after Xyl-A/dCF selection. Next, transduced Xyl-A/dCF-resistant fibroblast clones were isolated and hADA expression levels were determined. The average activities of the three tested constructs was not significantly different. For all three constructs an approximately 10-fold variation in hADA expression levels was measured between individual clones (Table 2) . Hence, as expected, in non-T cells the CD2-LCR did not affect the integration site-dependent expression pattern of the LgAL(⌬Mo+PyF101) construct.
Expression of hADA retroviruses bearing the CD2-LCR in transduced T cells Human ADA − SCID T cells were transduced by cocultivation with four CD2-LCR containing vectors that were shown not to recombine upon replication and with the basic construct without a CD2-LCR insert. Transduced T cell pools exhibited low provirus copy numbers (around 1%), even though the conditions appeared to be favorable for high transduction frequency, ie the T cell cultures expanded 4.5-to eight-fold during 3 days cocultivation and retroviral titers measured at the end of the cocultivation were in the order of 10 4 CFU/ml (not shown). Since low transduction frequencies make a reliable ADA activity measurement difficult, we chose to include a selection step in the procedure. Two independent Xyl-A/dCF selections yielded T cell pools with proviral copy numbers ranging from 0 to 1 and from 0.3 to 0.8, respectively (experiments I and II, Table 3 ). These selected pools were analyzed for ADA and purine nucleoside phosphorylase (PNP) activities, with PNP serving as an internal control for sample quality. The ADA/PNP ratio was subsequently divided by the proviral copy number present in each sample. As can be seen in Table 3 , the incorporation of CD2-LCR fragments in retroviral constructs did not improve the average expression levels of hADA in T cells. In contrast, the 881 nt CD2-LCR fragment insertion into the LTR significantly decreased the expression of proviral hADA.
Long-term analysis of mice transplanted with transduced bone marrow cells To study expression patterns in mature hemopoietic cells derived from transduced stem cells that subsequently underwent differentiation, we performed two independent transplantation experiments with transduced mouse bone marrow cells (BMC). The BMC were cocultured for 3 days with the producer clones giving the highest titers of LgAL(⌬Mo+PyF101), C2F or N8F virus, and were subsequently transplanted into at least 15 irradiated recipients per group. Fourteen or 9 months after transplantation (experiments 1 and 2, respectively) the mice were killed and single cells from bone marrow, thymus and spleen were isolated. These samples were analyzed for the presence of the vector by PhosphorImager measurement on Southern blots and for hADA expression by zymogram analysis. In 45% of the mice, transduced cells were detected with frequencies up to 57%. In general, spleen cells showed a higher transduction frequency than bone marrow and thymus cells. Human ADA activity could only be detected in four spleen samples carrying the C2F construct and in one bone marrow sample carrying the LgAL(⌬Mo+PyF101) construct. The hADA activity levels did not correspond to the transduction frequencies. For example, samples carrying the provirus in only 4 or 8% of the cells (mouse numbers 43 and 109) clearly showed hADA expression whereas 30 or 38% transduced samples (mouse numbers 38 and 36) had undetectable hADA expression levels (see Figure 3 ) In thymus, hADA expression could not be detected at all. Although, as a result of low protein yield, the sensitivity of hADA detection in thymus samples was lower than for the other tissues it could be concluded that the CD2-LCR did not direct high levels of hADA expression in thymus cells. Taken together, the results strongly suggest that the CD2-LCR in this retroviral context does not confer expression levels in an LCR-like manner.
Discussion
In this study we designed new retroviral vector constructs carrying the CD2-LCR and ⌬Mo+PyF101-LTR to improve expression levels of the genes introduced into T cells. We analyzed the functioning of our constructs in transgenic mice, in mature T cells and in hemopoietic cells of mice transplanted with modified bone marrow cells. In transgenic mice, neither the polyoma virus F101 mutant enhancer nor the CD2-LCR overcame the expression block observed for wild-type MuLV promoters in the germ line. Because the ⌬Mo+PyF101-LTR has previously been shown to be active in EC cells, our findings indicate that the mechanism of LTR repression in transgenic mice is different from that in EC cells. The fact that addition of an LCR to a retroviral construct does not result in expression in transgenic mouse tissues is in congruence with the study by McCune and Townes. 33 They investigated the influence of retroviral LTRs on the expression of ␤-globin constructs in transgenic mice. Addition of LTRs to a construct comprising the human ␤-globin gene, the homologous ␤-globin promoter and a region of the ␤-globin LCR completely blocked human ␤-globin expression in erythrocytes. Another construct in which the ␤-globin gene was flanked by two LCR fragments between two LTRs showed only marginal expression. Hence, LTRs seriously down-regulated the ␤-globin promoter and this could not be relieved by LCR sequences. Our study suggests that the repression of LTRs in the germ line is also dominant over the action of the CD2-LCR, implying that this could be a general phenomenon. Next, we generated eight different recombinant retroviruses containing the PyF101 enhancer and a CD2-LCR fragment. Similar to retroviruses containing ␤-globin LCR fragments, not all CD2-LCR insertions rendered stable viruses. Three constructs showed rearrangements in 20-100% of transduced cells. The 2.1 kb CD2-LCR fragment showed a more than two-fold higher incidence of recombination as compared to the 0.88 kb fragment. Moreover, insertion of the 2.1 kb fragment in the LTR (forward orientation) always led to rearrangement of the vector. Still, for all constructs the obtained retroviral titers were not decreased as compared with the basic vector lacking the CD2-LCR, regardless of whether rearrangements took place. This contrasts with the observations on many ␤-globin LCR containing retroviruses. [23] [24] [25] The other five constructs could reproducibly be used to produce stable recombinant retroviral vectors with CD2-LCR inserts. This allowed further study of the action of the CD2-LCR in retroviral constructs.
Mouse fibroblasts transduced with CD2-LCR containing retroviruses or with the basic vector lacking the CD2-LCR exhibited average expression levels that were not significantly different. For all constructs tested a large variation in expression levels was observed between different transduced clones. This shows that the position effects of proviruses in fibroblasts are not influenced by the CD2-LCR. Thus, the CD2-LCR does not appear to affect LTR promoter-dependent expression in non-T cells.
In ADA − SCID T cells transduced with the basic vector LgAL(⌬Mo+PyF101), hADA enzyme activity levels were reached that were well above the levels observed in T cells of healthy ADA + donors. 34 Unexpectedly, the average expression levels of most CD2-LCR containing retroviruses were quite similar to that of LgAL(⌬Mo+PyF101). The N8F vector, however, exhibited significantly lower hADA expression levels. This suggests that the 881 nt LCR fragment contains a repressor element with an orientation-dependent effect on the retroviral promoter.
We do not feel that the lack of a detectable LCR effect can be explained by the selection procedure needed to obtain a sufficiently transduced T cell population to allow expression analysis, since our findings on transduced fibroblasts and on N8F-transduced T cells show that the selection does not eliminate low-expression cells. Thus, highly variable expression levels between different genomic integration sites could not have been masked by the selection.
An alternative explanation could be that the position effects on retroviral expression in T cells mainly become apparent after transduced cells have undergone a maturation process. To investigate this we performed hematopoietic stem cell transduction experiments with C2F and N8F vectors. Our results show that in mature hemopoietic cells of long-term reconstituted mice the hADA expression levels were not copy number-dependent nor T cell-specific. Hence, in addition, in the progeny of transduced hemopoietic stem cells, position effects remained evident. Thus, the integration site-dependent repression of the retroviral promoter could not be relieved by insertion of a CD2-LCR into the vector. Apparently, the repression is dominant over the action of the LCR. Studies are underway to identify sequences in the retroviral genome involved in the suppression mechanism. 35 By deletion or mutation of these sequences improved viral vectors may be developed. It is possible that an LCR-like effect can be achieved in the context of such a new generation retroviral vector. However, the conclusion from this study is that the CD2-LCR does not affect the expression pattern of our current viral vectors.
Materials and methods
Construction of CD2 locus control region-containing retrovirus vectors
The recombinant retroviral construct pLgAL (⌬Mo+PyF101), 9 containing the hADA cDNA, was used as the basic vector. To generate constructs Mo-A-Mo and Py-A-Py (Figure 1b ) the basic vector was digested with either KpnI (cuts in U5) or NheI (cuts 5′ of the enhancer in U3). Both digestions render a fragment consisting of the plasmid backbone with two incomplete LTRs and a provirus fragment also flanked by two incomplete LTRs. The two plasmid backbones were circularized by religation thereby forming one LTR, either the wild-type LTR or the ⌬Mo+PyF101-LTR. Subsequently, these plasmids were digested with NheI (on KpnI religated plasmid) or KpnI (on NheI religated plasmid) and ligated to the above described provirus fragments. For the isolation of the CD2-LCR sequence located in the 3′ region of the human CD2 gene, 18 the construct GSE1502 (a kind gift from D Kioussis, MRC, London, UK; Figure 1a ) was used. Two different fragments were isolated; a 2076 nt HindIII fragment (immediately adjacent to the polyadenylation signal of the hCD2 gene) and an 881 nt AflIII fragment (starting 432 nt 3′ of the polyadenylation signal). Both fragments were provided with a blunt end with Klenow-polymerase. Constructs Py-A-LCR-Py and Py/LCR-APy/LCR are similar to Py-A-Py but carry the blunted 2076 nt LCR fragment inserted in the ClaI site in the envelope gene or in both NheI sites in the 5′ and 3′ LTRs. For the production of recombinant retroviruses, the basic vector was digested with ClaI or NheI and blunted. The two LCR fragments were cloned into these two sites in the normal 5′ Ͼ 3′ orientation of the CD2-LCR (forward) or in the 3′ Ͼ 5′ orientation (reverse). This resulted in eight different novel retroviral constructs, which are referred to by the following name code: 'C' for insertion of the CD2-LCR into the ClaI site or 'N' for insertion into the NheI site; '2' for the 2076 nt fragment or '8' for the 881 nt fragment; and 'F' for the forward orientation or 'R' for the reverse orientation. The eight constructs are thus called pC2F, pC2R, pN2F, pN2R, pC8F, pC8R, pN8F and pN8R (see Figure 1c) .
Generation of transgenic mice
Four constructs were used to generate transgenic mice (see Figure 1b) . EcoRI-SalI digested DNA was injected into zygotes from superovulated BCBA (C57BL/ KaLwRij × CBA/BrARij)F1 mice. Transgenic mice were generated essentially as described. 36 Cell culture and virus titration All fibroblast cell lines used were maintained in high glucose (4.5 g/l) ␣-modified Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin (Gist-brocades, Delft, The
Briefly, a 2-h vector supernatant was harvested from 70% confluent virus-producing cells. At day 1, 10 5 NIH/3T3 cells were seeded in a 60-mm dish with 4 g/ml polybrene in culture medium. The next day, the medium was replaced with 1 ml of serially diluted vector supernatant. After 2 h of incubation, 4 ml culture medium was added. At day 3, the cells were reseeded 1:40 in medium containing 4 m xylofuranosyl-adenine (Xyl-A) and 10 nm deoxycoformycin (dCF). 37 Xyl-A and dCF were kind gifts from Dr NR Lomax (Drug Synthesis and Chemistry Branch, NCI, Bethesda, MD, USA) and Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company (Ann Arbor, MI, USA), respectively. After approximately 10 days selection, resistant colonies were scored.
Generation of amphotropic recombinant retrovirus producing cell lines
Five micrograms of DNA of the retrovirus constructs was transfected into the ecotropic packaging cell line GP+E-86, 38 using Lipofectin reagent (Gibco BRL) in the presence of 10% FCS. Transfectants producing a functional hADA enzyme were isolated through a selective culture for 10 days in medium containing Xyl-A/dCF as described above. When cells reached 70% confluency, a 2-h vector supernatant harvest in nonselective culture medium was performed. Filtered (0.45 m pore size) vector supernatant was used for the transduction of the amphotropic packaging cell line Gp+envAm12 39 after overnight preincubation of the cells with 4 g/ml polybrene. GP+envAm12 cells producing a functional hADA enzyme were isolated through Xyl-A/dCF selection as described above. Individual GP+envAm12 clones were isolated and expanded. POC-1 9 and POAM-P1 31 cell lines, which contain 1 or 10 proviral copies per cell of LgAL(⌬Mo+PyF101) and shed titers of 1.2 × 10 3 /ml or 1.0 × 10 5 /ml, respectively, served as controls.
Cultivation and transduction of hADA − SCID T cells and mouse fibroblasts The T cells used were derived from an ADA − SCID patient. 28 They were maintained in RPMI 1640 medium buffered with 2 g/l bicarbonate and 4.8 g/l Hepes (Gibco BRL, Life Technologies, Paisley, UK), supplemented with 10% human serum, 25 U/ml recombinant human interleukin-2 (rIL-2; Eurocetus, Amsterdam, The Netherlands), 4 mm glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 1 g/ml indomethacin (Sigma, St Louis, MO, USA) and 1 g/ml leucoagglutinin (Sigma) in the presence of irradiated (25 Gy) allogenic peripheral blood lymphocytes and Epstein-Barr virus-transformed lymphoblastoid B cell lines as feeder cells. 32 Cells were plated in round-bottomed 96-well microtiter plates and incubated at 37°C in 5% CO 2 . Cells were harvested and replated with new feeder cells and fresh medium at weekly intervals.
To transduce the T cells with recombinant retroviruses, 5 × 10 4 T cells/ml were cocultured for 72 h with a confluent irradiated (20 Gy) monolayer of virus-producing cells in AIM-V medium (Gibco BRL) supplemented with 10% heat-inactivated human serum, rIL-2, glutamine, penicillin and streptomycin in concentrations as above and 1 g/ml polybrene (Sigma). As a negative control, T cells were cocultivated with the parental packaging cell line GP+envAm12 (mock infection). After expansion of the cells as described above, transduced T cells were selected for 72 h in the cocultivation medium lacking polybrene and serum, but with the addition of 4 m Xyl-A and 10 nM dCF.
Transduction efficiency was determined by measurement of T cell proliferation in the presence or absence of 4 m Xyl-A and 10 nm dCF. T cells (in log phase) were cultured in flat-bottomed microtiter plates (4 × 10 4 cells per well) in serum-free AIM-V medium with 4 mm glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 50 U/ml rIL-2 in a final volume of 100 l for 48 h at 37°C in 5% CO 2 .
3 H-Thymidine was added during the last 18 h of culture. Cells were spotted on a filter, that was subsequently dried at 80°C. Radioactivity on the filter was counted in a liquid scintillation counter using Opti-fluor LSC-cocktail (Packard Instruments, Meriden, CT, USA). Results are obtained from quadruplicate cultures.
To transduce mouse fibroblasts with recombinant retroviruses, 10 5 NIH/3T3 cells were seeded into 60 mm dishes in culture medium with 4 g/ml polybrene and the next day the medium was replaced with vector supernatant harvested as above. After overnight incubation, cells were trypsinized and seeded into 96-well plates (at limiting concentrations down to 0.3 cells per well) or into a 25-cm 2 culture flask. Cells were grown in the presence or absence of Xyl-A/dCF selection as above.
Transduction and transplantation of mouse bone marrow cells BCBA (C57BL × CBA) F1 mice were bred and maintained under specified pathogen-free conditions. Bone marrow was harvested from femors and tibiae of 21-week-old BCBA mice (experiment 1) or from 40-week-old BCBA mice that had received 5-fluorouracil (i.v. 150 mg/kg) 2 days earlier (experiment 2). The cells were separated on a discontinuous metrizamide gradient to remove most of the erythrocytes and granulocytes and to enrich for primitive hemopoietic cells. 40 The virus producing cells were seeded 1 day before cocultivation such that they were approximately 90-100% confluent on the following day. Prior to initiation of the cocultivation the feeder cells were irradiated (20 Gy, 0.70 Gy per min, 137 Cs gamma rays). The cocultivation was started by replacing half of the culture medium by fresh medium containing bone marrow cells (2 × 10 6 nucleated cells per ml), polybrene (0.8 g/ml), murine IL-3 (10 U/ml; R&D Systems, Abingdon, UK) and human IL-1␣ (20 U/ml; Biogen, Geneva, Switzerland). After 3 days cocultivation all cells were collected and equivalents of 2 × 10 6 input cells were transplanted into lethally irradiated (8.5 Gy, 0.70 Gy per min, 137 Cs gamma rays) BCBA mice (21-week-old and 40-week-old for experiments 1 and 2, respectively). For up to 30 days following transplantation the mice were fed 20 mg/l delvocid (50% natamycin, 50% lactose; Gistbrocades) 100 mg/l polymyxin B sulfate USP (Genfarma, Maarssen, The Netherlands), 100 mg/l Cyproxin-750 (75% ciprofloxacine; Bayer, Leverkusen, Germany) and 40 g/l sucrose via their drinking water.
Thymus, spleen and bone marrow were isolated from long-term reconstituted mice and passed through a fine mesh to obtain single cell suspensions. The cells were subsequently pelleted, flash frozen and stored at −80°C until analysis.
Southern analysis DNA was isolated as described. 41 Five or 10 g DNA was digested with the appropriate restriction enzyme(s), subjected to electrophoresis through a 0.7% agarose gel, transferred to Hybond-N + nylon membranes (Amersham, Amersham, UK) and hybridized to 32 P-labeled probes according to standard procedures. To obtain hADA probes, fragments were isolated from pAMG1: 42 an 881 bp SstII-BglII fragment that comprises hADA sequences 5′ of the BglII site in the hADA-cDNA, a 521 bp BglII-SstII fragment comprising hADA sequences 3′ of the BglII site in the hADA-cDNA, and the complete 1402 bp SstII hADA-cDNA fragment. As CD2-LCR probes, the following fragments were isolated from GSE1502: a 480 bp HindIII-NheI fragment (5′ probe), a 553 bp SstI-HindIII fragment (3′ probe), and the complete 2076 bp HindIII fragment.
Provirus integrity was analyzed by Southern analysis after digestion with SstI, Acc65I, NheI and/or BglII according to standard procedures. Provirus copy numbers in transduced cell populations were determined by quantitative Southern analysis on NcoI-digested DNA. Digestion of all different retrovirus constructs used in this study with NcoI releases a 1.3 kb hADA cDNA fragment hybridizing to the 881 bp or complete hADA probes. These probes also hybridize to genomic ADA fragments in NcoI-digested DNA. Southern blots were analyzed by phosphor screen autoradiography using a Molecular Dynamics (Sunnyvale, CA, USA) PhosphorImager (400A). The bands were quantified by ImageQuant area quantification. The density of an endogenous genomic ADA fragment in ADA − SCID T cells or in mouse cells was used as an internal loading control in each sample. The provirus copy number in transduced cell populations was calculated by comparing the corrected density of the proviral fragment to those of titration samples of ADA − SCID T cells or mouse fibroblasts containing a single LgAL(⌬Mo+PyF101) provirus per cell diluted in negative ADA − SCID T cells or mouse fibroblasts.
ADA activity assays
Human and mouse ADA isozymes were detected in lysates of transduced mouse fibroblasts and in single cell suspensions of transgenic mouse tissues and of spleen, bone marrow or thymus of transplanted animals using a zymogram assay as described. 43 In this assay, human and mouse ADA isozymes are electrophoretically separated and subsequently stained for ADA enzymatic activity. The endogenous mouse ADA activity served as an internal loading control. Human ADA expression levels were semi-quantified by serial dilution of the samples and comparison to the endogenous mouse ADA activity.
To measure human ADA activity in ADA − SCID T cells, frozen pellets of 5 × 10 6 T cells were sonicated on ice in 0.15 ml 25 mm Tris-HCl pH 7.4, 15 mm KCl, 1 mm DTT, 1 mm EDTA. Lysates were cleared by centrifugation at 13 000 g for 3 min at 4°C. Protein concentrations were determined by the Lowry method 44 with bovine serum albumin as standard. ADA and purine nucleoside phosphorylase (PNP) activities were analyzed as described. 34 The PNP activity served as an internal control for sample quality. The relative human ADA activity is expressed as the ratio ADA/PNP activity. 34 
